HomeHealthcare & Life SciencesBiotechnology Peripheral Myelin Protein 22 Gene Related Disorder Market

LATAM Peripheral Myelin Protein 22 Gene Related Disorder Market Size & Outlook, 2026-2034


LATAM Peripheral Myelin Protein 22 Gene Related Disorder Market Insights

  • As highlighted in Reed Intelligence analysis, the LATAM Peripheral Myelin Protein 22 Gene Related Disorder Market, valued at USD 158 Million in 2025, is estimated to achieve USD 334.03 Million by 2034.
  • The market is estimated to grow at a CAGR of 8.65% spanning 2026 to 2034.
  • By market size, Charcot-Marie-Tooth Disease Type 1A (CMT1A) led the Type category in 2025.
  • The Type segment led by Charcot-Marie-Tooth Disease Type 1A (CMT1A) is estimated to post the fastest growth, sustaining its position as the most lucrative during the forecast timeframe.

Other Key Findings


  • In 2025, LATAM contributed 10% to the overall global Peripheral Myelin Protein 22 Gene Related Disorder Market size.
  • By 2034, United States is anticipated to dominate the global market based on market size.
  • Brazil is expected to witness the fastest growth within LATAM, attaining USD 134.29 Million by 2034.

Report Summary

Report Scope Details
Base Year for Study 2025
Study Period 2022-2034
Historical Period 2022-2024
Forecast Period 2026-2034
Market Size In 2025 USD 158 Million
Market Size In 2034 USD 334.03 Million
Largest segment Charcot-Marie-Tooth Disease Type 1A (CMT1A)
Units Revenue in USD Million
CAGR 8.65% (2026-2034)
Segmnetation Covered
LATAM
  1. Brazil
  2. Mexico
  3. Argentina
  4. Colombia
  5. Chile
Type
  1. Charcot-Marie-Tooth Disease Type 1A (CMT1A)
  2. Hereditary Neuropathy with Liability to Pressure Palsies (HNPP)
Application
  1. Diagnostics
  2. Therapeutics
End-Use
  1. Hospitals and Clinics
  2. Research Institutes
  3. Diagnostic Laboratories
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Related Reports